×

RNS Number : 8189H

Dev Clever Holdings PLC

05 August 2019

 

Dev Clever Holdings plc

("Dev Clever" or "the Company") 

Vanguard: Fight for Rudiarius VR New Leisure Partner 

 

Dev Clever, a leading developer of mobile and immersive consumer experiences, is pleased to announce that its competitive multi-player, virtual reality game "Vanguard: Fight for Rudiarius" has been successfully installed in its first Teamsport indoor go-karting venue, in Birmingham UK.

 

Teamsport is the number one indoor go-karting operator in the UK, with thirty four indoor go-karting venues across the country.  The "Pay Per Play" competitive VR experience Vanguard: Fight for Rudiarius has been installed in Birmingham on a 10-week trial with a view to then rolling out the multiplayer VR experience to other Teamsport locations across the UK.    

 

The out of home, multi-player game allows players to compete against each other as space-age gladiators in full 360' virtual reality. The "Pay Per Play" game version of "Vanguard: Fight for Rudiarius" has been created specifically for installation in venues across the UK leisure and hospitality sector and has been developed using Dev Clever's proprietary immersive framework that enables rapid development of immersive, multiplayer games and experiences.  

 

Further releases of the Vanguard game are to include  "Pay to Download" and "In App. Purchase" versions which are downloadable for mobile users via the Apple App Store and Google Play Store, for VR users via the Oculus Store and PC users on windows, leading to full cross-platform integration to include users on PlayStation, Xbox and Nintendo Switch. 

 

 

Chris Jeffries CEO Dev Clever said:

 

Teamsport is an exciting new leisure partner for Dev Clever.  As the number one indoor go-karting operator in the UK they provide thousands of customers each month with a competitive motor sports experience. The out of home Vanguard game offers an extension to the customers experience and allows them to carry on the battle from the race track and compete as a group in competitive VR. I see this as an ideal consumer audience for Vanguard and I'm delighted to be working with the market leaders in this sector.   

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAEZLFBKVFXBBD

Close

×

Neville Registrars is delighted to welcome Elecosoft plc as the newest addition to its list of client companies.

Elecosoft provides integrated software and associated services to the worldwide architectural, engineering, construction and owner/operator (AECO) industries.

Further information can be found on the Company's website: https://www.elecosoft.com/

Close

×

RNS Number : 0503G

Midatech Pharma PLC

19 July 2019

 

 

19 July 2019

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

 

Midatech Announces Safety Results from First in Human Study for Injectable MidaCore® Gold Nano Particle Diabetes Vaccine Programme – MTX102

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive results from a first in human study of its MTX102 immuno-tolerising vaccine product candidate in diabetes.

 

The focus of this Phase I study is to assess the safety of MTX102.  Five recently diagnosed Type I diabetes patients, all meeting strict genetic parameters, were recruited onto the study and received the study drug.  MTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported. 

 

This is an important study of systemic injectable administration of Midatech's gold nanoparticle technology, MidaCore®.  It provides promising safety validation of the MidaCore® technology as a platform for the development of medications for use in humans.

 

Colin Dayan, Principal Investigator, said "This EU project brings together a consortium comprising eight complementary partners, including two small and medium enterprises, one technology transfer company and five academic laboratories, from four EU states (UK, France, the Netherlands and Sweden) and Israel.  We are pleased to have completed the initial project, based on Midatech's gold nanoparticle technology, to evaluate a vaccine approach for the treatment of Type 1 diabetes.  The study now enters a follow up stage, at the end of which we will review the data and programme, together with the EU consortium partners.

 

Craig Cook, CEO of Midatech Pharma PLC, commented: "This EU funded programme is an invaluable project to further develop, understand and evaluate Midatech's gold nanoparticle technology, MidaCore®.  This is the first human study to assess the safety of MidaCore® when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications."

 

The aim of the study to assess safety has been achieved and no further patients will be recruited.  All patients on the trial will now enter the follow up phase which will conclude around Q1 2020.

 

MTX102 is based on Midatech's MidaCore® technology platform of ultra-small gold nanoparticle drug conjugates.  MidaCore® is being developed as an immunotherapeutic as well as a chemotherapeutic platform.  In vaccines it represents an innovative approach that takes advantage of the multifunctional properties of gold nanoparticles to combine immunogenic peptides and tolerising agents and deliver them more efficiently to immune cells to dampen down autoimmune responses in diseases such as diabetes.

 

Midatech is part of a consortium of academic institutions and industry partners investigating the potential of MTX102 as a vaccine to prevent or limit the damage that occurs when the body attacks its own insulin producing cells in the pancreas.  This project is funded by the European Union up to the completion of Phase I study.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance) 

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring / Heather Armstrong

Tel: +44 (0)20 3934 6630

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

About Midatech Pharma PLC

 

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body.  The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D makes medicine better, lowers technical risks, accelerates regulatory approval and route to market, and provides newly patentable products.  The platform nature of the technologies allows the potential for multiple drug assets rather than being reliant on a single or limited programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain.  For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

 

Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our plans, goals, and milestones, our ability to successfully test, manufacture, produce or commercialise products for conditions using our drug delivery platforms, the ability for products in development, including MTX102, to achieve positive clinical results, the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions and the associated costs of such studies, trials or submissions, and other economic, business and/or competitive factors. The risks included are not exhaustive. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that we shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUWAARKNABAUR

Close

×

RNS Number : 8248F

Cadence Minerals PLC

17 July 2019

 

Cadence Minerals Plc

 

("Cadence Minerals", "Cadence" or "the Company")

 

Hastings Technology Metals (ASX:HAS) Confirms No Appeals on EPA Recommendation of Environmental Approval for Proposal to Mine & Process Rare Earths at Yangibana.

 

Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to announce Hastings Technology Metals (ASX:HAS) ("Hastings"), Cadence's joint venture partner at the Yangibana Rare Earth Project in the Gascoyne region of Western Australia ("Yangibana Project"), has announced that the Appeals Registrar (WA Office of the Appeals Convenor) has not received any appeals on the EPA Assessment Report, which recommends approval of the Yangibana Project subject to the proposed conditions.

Cadence owns 30% of the Yangibana North., Gossan, Hook, Kanes Gossan, Lions Ear and Bald Hill North Rare Earth Deposit which form part of the Yangibana Rare Earth Deposit. Probable Ore Reserves of some 2.1 million tonnes at 1.66% total rare earth elements are contained within 30% owned joint venture tenements. Further details of these reserves and pre-feasibility study can be found at: http://irservices.netbuilder.com/ir/cadence/newsArticle.php?ST=REM&id=2688632.

Highlights:

·      The Appeals Registrar (WA Office of the Appeals Convenor) has notified Hastings that they have received no appeals on the EPA's recommendation to approve the Yangibana Project.

·      Next step in the approvals process is consultation with the Decision Making Authorities ("DMAs"), i.e. Ministers for Water, Mines and Aboriginal Affairs to obtain their agreement to the implementation of the project in accordance with the proposed conditions.

The DMAs will be provided with the draft conditions (as detailed in the EPA Assessment Report) for their consideration and must then provide their agreement to the implementation of the proposal subject to the draft conditions. The Minister for Environment will then consider the proposal and EPA recommendation.

The Yangibana project includes the development of five open pit mines, groundwater abstraction, on-site processing of ore, tailings storage facilities, access and haul roads and supporting infrastructure such as accommodation facilities, administration buildings and an airstrip.

The full release can be found at: https://www.asx.com.au/asxpdf/20190717/pdf/446p7m8wcdgm40.pdf

– Ends –

 

For further information:

Cadence Minerals plc	+44 (0) 207 440 0647
Andrew Suckling
Kiran Morzaria
WH Ireland Limited (NOMAD & Broker)	+44 (0) 207 220 1666
James Joyce
James Sinclair-Ford
Novum Securities Limited (Joint Broker)	+44 (0) 207 399 9400
Jon Belliss

 

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

 

Forward-Looking Statements:

Certain statements in this announcement are or may be deemed to be forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'' ''could'' "should" ''envisage'' ''estimate'' ''intend'' ''may'' ''plan'' ''will'' or the negative of those variations or comparable expressions including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth results of operations performance future capital and other expenditures (including the amount. nature and sources of funding thereof) competitive advantages business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.  Many factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions competition environmental and other regulatory changes actions by governmental authorities the availability of capital markets reliance on key personnel uninsured and underinsured losses and other factors many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions. The Company cannot assure investors that actual results will be consistent with such forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDGGUQCMUPBURM

Close

×

Neville Registrars is pleased to announce that it will be exhibiting at The ICSA Annual Conference 2019 to be held on the 9th & 10th July (8.30am – 5.30pm) at the ExceL Conference Centre, London.

Please find us at Stand 31 where we will be delighted to discuss your Company's requirements and outline the numerous services/products we can offer.

Close

×

RNS Number : 4280E

ValiRx PLC

04 July 2019

 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

UPDATE RE VAL301

FOR THE TREATMENT OF ENDOMETRIOSIS

 

"ValiRx progresses VAL301 Clinical Development Plan"

 

London, UK., 04 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company's clinical team has signed an agreement to work with Aptus Clinical Ltd ("Aptus"), the UK based, clinical Contract Research Organisation ("CRO"), to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.

 

Aptus will be working with ValiRx on regulatory, technical and scientific areas, in order to bring VAL301 nearer to the clinic.

 

Endometriosis is a benign, oestrogen -dependent chronic condition, characterised by endometrial tissue growth outside of the uterus.  Symptoms including heavy painful periods, pain with intercourse and infertility are often severe and are associated with a decreased quality of life for young women. The condition affects an estimated 1 in 10 women during their reproductive years, equating to approximately 176 million women worldwide*, posing a high economic burden.

 

VAL301 is derived from the same active pharmaceutical ingredient as VAL201, which is currently in a Phase I/II clinical trial where the compound has demonstrated safety and has been well tolerated. These positive results will be used to strengthen the clinical application of the development programme.  Pre-clinical studies indicate that treatment with VAL301 should not affect bone density or fertility, two of the major problems associated with current medical treatments for endometriosis. ValiRx intends to develop VAL301 as a non-invasive, effective and better tolerated treatment for this debilitating condition.

*Source: https://www.ncbi.nlm.nih.gov/pubmed/30026507

 

Dr Satu Vainikka, CEO of ValiRx, commented: "Our agreement with Aptus represents an important stage in preparing the VAL301 compound for clinical study. I look forward to VAL301's future development and its potential to benefit women who suffer from this extremely painful condition".

 

Dr Steve McConchie, Co-founder & CEO of Aptus, added: "We are delighted to have been selected by ValiRx to work on the development plan options for VAL301 in endometriosis. We look forward to exploring some innovative opportunities with the team in order to optimise the programme delivery timelines and progress this important potential treatment rapidly to patients".

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

Notes for Editors

 

About Aptus

Aptus is a UK based, clinical CRO with particular expertise in oncology, rare diseases and advanced (cell and gene) therapies. The company provides design, set-up, management and monitoring of early phase clinical trials. In addition, it supports clients with a range of specialist services that include quality management frameworks, clinical governance support and a number of digital solutions that facilitate data storage, analysis and visualisations.

 

Aptus are partners in iMATCH (innovate Manchester Advanced Therapy Centre Hub), a consortium of experts from industry, academia and the NHS, funded by Innovate UK. The iMATCH objective is to accelerate the safe and effective delivery of advanced therapies to increasing numbers of patients within the NHS.  Aptus are also preferred suppliers to the Cell and Gene Therapy Catapult.

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCBRGDRXSGBGCX

Close

×

RNS Number : 3368E

Midatech Pharma PLC

03 July 2019

 

3  July 2019

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

 

MTX110 Update

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce an update on its key MTX110 programme.

 

MTX110 is designed for the treatment of childhood brain cancers such as Diffuse Intrinsic Pontine Glioma ("DIPG"), an ultra-rare highly aggressive and inoperable tumour located in the brain stem, that is universally fatal with an average life expectancy of 7 to 9 months.  Midatech is also evaluating MXT110 for the treatment of Glioblastoma Multiforme ("GBM"), which is a fast-growing form of brain cancer in adults.

 

The initial MTX110 study (PNOCO15) in DIPG patients, began in May 2018 and is a combined Phase I (safety) and Phase II (efficacy) programme.  Phase I is a dose escalating component originally designed with five dose levels; however, since MTX110 has been well tolerated in the patients treated to date, a further two higher dose levels have been added to the study. This Phase I component is scheduled to complete in Q3 2019.

 

Based on the Phase I progress to date, the Recommended Phase II Dose ("RP2D") has preliminary been set at the upper dosage level achieved in this Phase I component.  A further small cohort of three patients will now be treated to complete the "3+3 design", the traditional standard dose escalation schedule in the development of cancer therapeutics, and to confirm this RP2D dose, bringing the total number of patients treated at the final RP2D to five. We expect these patients will join the Phase II efficacy component, which is scheduled to start during Q3/4 2019, following confirmation from the US Food and Drug Administration.

 

Dr Sabine Mueller, Principal Investigator for the study said: "Midatech's MTX110 has shown promise as one of the most potent compounds against DIPG brain tumour cells in laboratory experiments.  In this first in human study of MTX110 we are encouraged by the excellent safety profile so far and look forward to completing the safety evaluation and commencing the efficacy assessment of the drug later this year."

 

Midatech's Chief Executive Officer, Dr Craig Cook, said: "We are delighted to be able to give this update on how the MTX110 programme is progressing. The patients have reacted very well from a safety perspective to MTX110 to date and we hope to advance to the Phase II component later this year and further evaluate MTX110 as a very promising therapy for DIPG, for which there are no effective treatments. We look forward to providing further updates as the development programme progresses."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance) 

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring / Heather Armstrong

Tel: +44 (0)20 3934 6630

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

About Midatech Pharma PLC

 

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body.  The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D makes medicine better, lowers technical risks, accelerates regulatory approval and route to market, and provides newly patentable products.  The platform nature of the technologies allows the potential for multiple drug assets rather than being reliant on a single or limited programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain.  For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

 

Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our plans, goals, and milestones, our ability to successfully test, manufacture, produce or commercialise products for conditions using our drug delivery platforms, the ability for products in development, including MTX110, to achieve positive clinical results, the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions and the associated costs of such studies, trials or submissions, and other economic, business and/or competitive factors. The risks included are not exhaustive. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that we shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDLIFLTDRIVIIA

Close

×

RNS Number : 5668D

Crimson Tide PLC

27 June 2019

 

Crimson Tide plc

 

("Crimson Tide" or "the Company")

 

Contract Wins and New Partnerships

 

Crimson Tide is pleased to report a number of contract wins for its mpro5 platform as well as new partnership agreements.

In the Middle East, the Company has won an mpro5 contract through their newly appointed partner Dcode.   The contract is for one of the leading waste management companies operating in the region and provides a solid platform to build out a stronger presence in 2020.  It is expected that the deployment will extend to several hundred users during the course of the next 12 months.

Crimson Tide is in the process of finalising a contract with Compass Group in Denmark. This promises to be the first of several countries rolling out mpro5 for Compass Group, where the Company aims to expand its footprint across the group. Compass currently operates in 45 countries.

On the subject of Internet of Things (IoT), the Company is excited by its partnership with KoolZone, experts in IoT monitoring across a number of sectors. Integrating KoolZone's extensive suite of sensors into mpro5 strengthens and broadens the unique offering in the IoT market of directing workflow as a result of sensor readings. KoolZone have expanded the catalogue of sensors available within mpro5 and their expertise enhances Crimson Tide's ability to match the best sensors with each mpro5 IoT opportunity.

Crimson Tide has won a contract for an innovative pilot in Ireland with a local county council utilising both mpro5's IoT and mobile workflow features.  This appears to be one of the first of its kind in this market sector and whilst it is too early to estimate the longer-term impact, there is a significant need to automate much of the paperwork and processes in this sector.

A new contract has been signed with Interserve for three years. The group has been a loyal customer for many years and uses mpro5 to deliver industrial cleaning and security auditing across a multitude of large customers such as the BBC, Sainsbury's and the NHS.

Barrie Whipp, Executive Chairman, commented:

 

"The sales strategy implemented at the end of 2018 is bearing fruit in what readers will understand is a market with uncertainties. Our ability to grow our long term contracted revenues demonstrates how robust our model is. I reiterate my confidence in the sales growth strategy that commenced in 2018"

 

Enquiries:

 

Crimson Tide plc                           Barrie Whipp / Luke Jeffrey	01892 542444
Arden Partners John Llewellyn-Lloyd / Dan Gee-Summons	020 7614 5900

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFFMRTMBTTBFL

Close

×

RNS Number : 2399D

Bidstack Group PLC

24 June 2019

 

RNS Reach

24 June 2019

Bidstack Group PLC ("Bidstack" or "the Company")

Results of Independent Study by Lumen Research

Bidstack Group plc (AIM: BIDS.L), the native in-game advertising group, is pleased to announce the results of an independent study commissioned by Bidstack which used eye tracking technology to measure and predict visual engagement with advertisements across several of its gaming titles.

The study was carried out by Lumen Research Limited, an attention technology company which has developed eye tracking software. Eye tracking offers a scientific and objective measure of the reality of attention. Instead of asking questions about what people thought they saw, Lumen's technology monitors what they actually looked at.

The study was designed to discover how much attention Bidstack adverts receive during a typical gamer session, to identify the kind of in-game ads that perform best and to compare native in-game advertising to digital browsing norms.

The results of the study were extremely positive for Bidstack. Bidstack's ads outperformed online browsing norms across all the titles tested, in some cases by more than double. When gamers who play every day interacted with Bidstack's ads they performed well above industry standards – demonstrating their value as an audience.

James Draper, CEO of Bidstack, commented, "We are thrilled with the outcome of this study which gives us independent proof that our product works in a demonstrable way for our clients.

"The results indicate that our advertising inventory outperforms display advertising in terms of brand recall, when exposed to a gaming audience which is an incredible result for the new industry and vertical we are building. "We are working to create a net new advertising category and, in doing so, media planners across the world will begin to recognise native in-game advertising alongside existing categories such as out of home or online display advertising.

"Bidstack is working through a number of independent viewability, brand safety and verification studies – to showcase the impact of our inventory.

"This study has helped us to understand where the premium placements are in-game and to refine our creative guidelines by game and environment, for example football vs racing games. This continued research is helping us define viewability in our various gaming environments and to evolve our programmatic pricing structure.

The positive results have come at a good time for the business and represent another step forward in our development along with our recent award of a DTSG Brand Safety Seal."

Mike Follett Managing Director at Lumen Research, said: "We were really excited about the opportunity to work with Bidstack as gaming is a growing media channel with relatively little existing research. As attention specialists, we worked closely with the Bidstack team to understand the nuances of their inventory and grasp how their audience interact with their in-game ads.

"Our bespoke approach involved utilising our proprietary eye tracking software across a diverse demographic sample, with an even gender split and an 18-65+ age range.

"Our objective was to measure in-game attention, identify the ads that performed best and benchmark the results against digital browsing norms. The findings showed consistent engagement rates from participants and that, crucially, for "every day gamers" Bidstack's ads outperformed online browsing norms in all of their titles."

~ENDS~

Contacts

Bidstack Group PLC

James Draper, CEO                                                                             +44 (0) 7850 341 885

SPARK Advisory Partners Limited (Nomad)

Mark Brady/Neil Baldwin/James Keeshan                                           +44 (0) 203 368 3550

Peterhouse Capital Limited (Broker)

Eran Zucker/Lucy Williams/Duncan Vasey                                         +44 (0) 20 7409 0930

Notes to editors

Bidstack

Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms. Its proprietary API technology is capable of inserting adverts into natural advertising space within video games across multiple video games platforms (mobile, PC and console).

Bidstack's customers are games publishers and developers and advertising agencies, brands and programmatic advertising platforms. Bidstack contracts exclusive access to the native in-game advertising space within video games from their developers or publishers and sells that advertising space either direct to specific brands and their agencies or through programmatic advertising platforms.

DTSG

The Digital Trading Standards Group (DTSG) was set up in 2012 to bring the industry together to propose guidelines aimed at significantly reducing the risk of misplacement of advertising across the digital trading ecosystem.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRALLFVSRDISFIA

Close

×

RNS Number : 8083C

ValiRx PLC

20 June 2019

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

CLINICAL UPDATE

 

 

MHRA and REC approve a major update to the trial of VAL201 including the appointment of a Principle Investigator to the clinical team

 

Results from the first clinical trial of VAL201 are being prepared for an independent evaluation following the completion of the current patient group.

 

London, UK, 20 June 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on its therapeutic drugs, VAL201 and its current clinical status.

 

VAL201 clinical trial

ValiRx is pleased to announce that based on its clinical results, a substantial amendment to the clinical trial protocol has received regulatory approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") and the Research ethics committee (REC)

 

Following approval of the substantial amendment, an authoritative prostate cancer specialist, Dr Mark Linch has been appointed as Principal Investigator to the clinical trial team at University College London Hospital ("UCLH").  Dr Linch is an Honorary Senior Lecturer at University College London (UCL) Cancer Institute, where he leads the Uro-oncology Biology Group, and he is also a Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer at UCLH.  Dr Rebecca Kristeleit continues with the study as Chief Investigator.

 

To date, the results generated by the trial, aided by sizable analytical methods developments, have shown that safe toxicological limits can be significantly elevated and applied to much higher levels in humans, than was suggested by the pre-clinical studies. The approval given to relax the restrictions previously applied to the trial, mean that a more effective use of VAL201 can be achieved, with respect to concentration and timing and regarding increased flexibility in the administration of the drug.

 

Additionally, the amendment relating to dosing strategies means that, in light of accumulated clinical data, the Company is able to develop further protocols. These will be designed to evaluate a range of defined therapeutic approaches that are to be tested against each other, to determine the most effective approach, in terms of disease management, cost effectiveness and patient welfare, in further clinical trials. These protocols will be the precursor to seeking approval to conduct trials aimed at gaining sufficient data to secure partnering and then Market Approval Application.

 

ValiRx reports that the trial thus far has met all the primary and secondary endpoints. The safety and tolerability results continue to be acceptable and further evidence of the compound's positive effect in reducing the progress of prostate cancer has been witnessed. The data from the trial is currently being collated for examination by independent third party experts. The approval of the amendment further validates the Company's clinical development throughout VAL201's First-in-Human Trial. Further information connected to the data and the results and findings from the trial will form the basis of a report outlining the compound's clinical profile and behaviour, which will be published in due course.

 

Dr George Morris, COO of ValiRx, commented:

"This substantial amendment has taken a lot of effort from the whole team both internal and by all our service providers to achieve. I am profoundly grateful to them all. The most gratifying thing is that our original pre-clinical experimental data has held up well and been vindicated throughout the whole of this first-in-human trial. Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited (Broker) Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDUKUVRKVANAAR

Close